Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by robertshawon Sep 21, 2017 9:06am

78 Views

Post# 26724578

RE:RE:180-days cystoscopy of low-dose patient #1 = Sept. 26

vestor111 wrote:

BUMP!

Looks like TLT's CEO will have managed its burn rate to get to that pivotal date. Wise.
All that, while confirming science-based results for 3 new late-stage cancer indications:

Theralase Lead Anti-Cancer Drug Effective in the Destruction (98%) of Throat Cancer
September 19, 2017

Theralase Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug
September 12, 2017

Theralase Anti-Cancer Drugs Effective in the Destruction (96%) of Cervical Cancer
September 05, 2017

Theralase Anti-Cancer Drugs Independently Verified and Validated
August 22, 2017

Theralase Anti-Cancer Technology Effective for the Destruction (100%) of Lung Cancer
August 08, 2017

Theralase PDT Technology Used to Treat Fourth Patient for Bladder Cancer
August 01, 2017

Theralase Achieves (3/3) Exploratory Endpoint of Efficacy for Anti-Cancer Technology
July 25, 2017

_________________

Getting closer to the next set of human data, time to be more precise:

180-days cystoscopy of low-dose patient #1, initially treated March 30 = Sept. 26
180-days cystoscopy of low-dose patient #2, initially treated April 12 = Oct. 9
180-days cystoscopy of low-dose patient #3, initially treated April 18 = Oct. 15
90-days cystoscopy of high-dose patient #1, initially treated July 20 = Oct. 18

Calculate Duration Between Two Dates – Results

If RW is smart enough, he should push the Pp as late as possible to get the 4th patient 's result out, maybe he could consider cut his salary a little bit to convert it to warrant and fund the company for at least half a month extra till mid November, Until we get phase 2 permission, with the share price surges significantly compares with the current level,he would get huge reward by such a wise decision.

Bullboard Posts

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta